Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track AZN with free AI briefings, catalyst countdowns, and dilution alerts.

AZN · AstraZeneca PLC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$8.2B Cash on Hand
CF+ Cash Runway
0.2% Short Interest
$208.07 Analyst Target (12)
Follow AZN by email Get an email when AZN reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about AZN, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Anifrolumab
FDA approved Jul 2021 · Saphnelo
Systemic Lupus Erythematosus N/A · NCT07913919 Recruiting
Durvalumab
FDA approved May 2017 · Imfinzi
Non-Small Cell Lung Cancer Phase 3 · NCT05221840 Active not recruiting
Selumetinib
FDA approved Apr 2020 · Koselugo
Locally Advanced or Metastatic Non Small Cell Lung Cancer Stage IIIb… Phase 3 · NCT01933932 Active not recruiting
Eplontersen
FDA approved Dec 2023 · Wainua (Autoinjector)
Transthyretin Amyloid Cardiomyopathy Phase 3 · NCT06194825 Active not recruiting
Olaparib
FDA approved Dec 2014 · Lynparza (discontinued)
Endometrial Neoplasms Phase 3 · NCT04269200 Active not recruiting
Baxdrostat
FDA approved May 2026 · Baxfendy
Uncontrolled Hypertension Phase 3 · NCT06034743 Completed
Benralizumab
FDA approved Nov 2017 · Fasenra
Eosinophilic Granulomatous Vasculitis Phase 3 · NCT04157348 Active not recruiting
Tezepelumab
FDA approved Dec 2021 · Tezspire
Severe Asthma Phase 3 · NCT07363642 Recruiting
Tremelimumab
FDA approved Oct 2022 · Imjudo
Combined Hepatocellular and Cholangiocarcinoma Phase 2 · NCT06855225 Not yet recruiting
Osimertinib
FDA approved Nov 2015 · Tagrisso
Carcinoma Phase 2 · NCT03778229 Active not recruiting
Lenbelintide Obesity or Overweight Phase 3 · NCT07776509 Recruiting
Doxorubicin Large B-cell Lymphoma Phase 3 · NCT07911553 Not yet recruiting
Elecoglipron Obesity Phase 3 · NCT07775404 Recruiting
FLOT Chemotherapy Gastric Phase 3 · NCT07877818 Recruiting
Monalizumab Non-Small Cell Lung Cancer Phase 3 · NCT05221840 Active not recruiting
Oleclumab Non-Small Cell Lung Cancer Phase 3 · NCT05221840 Active not recruiting

Also used in these trials (approved or third-party drugs, not AZN's own candidates): Cyclophosphamide, Docetaxel Anhydrous, Rituximab, Regorafenib, Prednisone, Polatuzumab Vedotin, Lomustine, Mepolizumab, Pembrolizumab, Paclitaxel, Pegfilgrastim, Adjuvant durvalumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

AZN holds $8.2B in cash and short-term investments and its operations are currently cash-flow neutral or positive.

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when AZN files for a raise →

📈 Recent Insider Activity (Form 4)

Trade dateInsiderTransactionSharesPriceOwned after
2026-10-06
filed 2026-10-08
Sharma Mani
Award (A) 2 $159.80 19,291
2026-09-08
filed 2026-09-11
Sharma Mani
Award (A) 1 $162.60 19,289
2026-08-08
filed 2026-09-11
Sharma Mani
Purchase (P) 20 $160.57 19,288
2026-08-06
filed 2026-08-07
Sharma Mani
Award (A) 2 $163.34 19,267
2026-07-06
filed 2026-07-08
Sharma Mani
Award (A) 2 $190.43 19,265

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

Get the full AZN picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for AZN and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.